SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP issued a shareholder-solicitation notice naming ARS Pharmaceuticals, Inc. (SPRY) as the target of a class action lawsuit. The firm is reminding investors who purchased SPRY shares between March 9 and June 24, 2026, of the October 5, 2026 lead plaintiff deadline.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.